PMD - Psychemedics Corp Stock Price, Fair Value and News

2.56USD-0.09 (-3.40%)Market Closed

Market Summary

USD2.56-0.09

Market Closed

-3.40%

PMD Stock Price

View Fullscreen

PMD RSI Chart

PMD Valuation

Market Cap

14.9M

Price/Earnings (Trailing)

-3.58

Price/Sales (Trailing)

0.67

EV/EBITDA

-3.79

Price/Free Cashflow

-9.08

PMD Price/Sales (Trailing)

PMD Profitability

EBT Margin

-15.56%

Return on Equity

-62.26%

Return on Assets

-33.7%

Free Cashflow Yield

-11.01%

PMD Fundamentals

PMD Revenue

Revenue (TTM)

22.1M

Rev. Growth (Yr)

-12.36%

Rev. Growth (Qtr)

-12.38%

PMD Earnings

Earnings (TTM)

-4.2M

Earnings Growth (Yr)

-37.35%

Earnings Growth (Qtr)

54.98%

Breaking Down PMD Revenue

Last 7 days

-9.5%

Last 30 days

-13.5%

Last 90 days

-24.7%

Trailing 12 Months

-52.2%

How does PMD drawdown profile look like?

PMD Financial Health

Current Ratio

1.45

Debt/Equity

0.01

Debt/Cashflow

-19.22

PMD Investor Care

Dividend Yield

9.57%

Dividend/Share (TTM)

0.25

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	24.6M	23.6M	22.8M	22.1M
2022	25.7M	26.1M	26.0M	25.2M
2021	19.5M	22.3M	23.8M	24.9M
2020	35.4M	29.4M	24.7M	21.4M
2019	41.6M	40.1M	38.9M	37.7M
2018	40.4M	41.5M	42.5M	42.7M
2017	42.5M	42.5M	40.7M	39.7M
2016	26.9M	29.6M	34.4M	39.0M
2015	28.9M	28.2M	27.6M	27.0M
2014	27.5M	28.3M	28.9M	29.2M
2013	25.4M	25.4M	26.0M	26.9M
2012	24.3M	25.0M	25.1M	25.2M
2011	21.6M	22.5M	23.7M	24.1M
2010	0	18.0M	19.1M	20.1M
2009	0	0	0	17.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Psychemedics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 17, 2023	weisenhoff michael	acquired	-	-	4,000	-
Aug 17, 2023	kamin peter	acquired	-	-	14,000	-
Aug 17, 2023	davis robyn c	acquired	-	-	14,000	-
Aug 17, 2023	reynolds andrew	acquired	-	-	14,000	-
Aug 17, 2023	nevin darius g	acquired	-	-	14,000	-
Aug 17, 2023	doucot charles m	sold	-59,182	4.66	-12,700	executive vice president
May 22, 2023	kubacki raymond c jr	sold (taxes)	-7,395	4.93	-1,500	chairman, ceo & president
May 22, 2023	schaffer michael i	sold (taxes)	-1,848	4.93	-375	vp of laboratory operations
May 22, 2023	doucot charles m	sold (taxes)	-4,067	4.93	-825	executive vice president
May 15, 2023	doucot charles m	sold (taxes)	-4,383	4.87	-900	executive vice president

Which funds bought or sold PMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	0.05	-253,271	743,798	-%
Feb 14, 2024	CRAWFORD INVESTMENT COUNSEL INC	reduced	-37.39	-67,939	59,489	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	9.00	9.00	-%
Feb 14, 2024	22NW, LP	unchanged	-	-277,162	812,277	0.53%
Feb 14, 2024	Ancora Advisors LLC	reduced	-0.26	-79,748	231,393	-%
Feb 14, 2024	RBF Capital, LLC	reduced	-1.45	-151,856	420,741	0.03%
Feb 14, 2024	CANNELL CAPITAL LLC	sold off	-100	-296,932	-	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-98.69	-9,000	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-20.74	-33,187	47,952	-%

Are Funds Buying or Selling PMD?

Are funds buying PMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMD

No. of Funds

Unveiling Psychemedics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	4.58%	265,563	SC 13G/A
Feb 02, 2024	kubacki raymond c jr	4.3%	246,737	SC 13G/A
Dec 14, 2023	powell anderson capital lp	5.38%	312,199	SC 13G
Feb 14, 2023	kubacki raymond c jr	6.5%	379,712	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.15%	290,463	SC 13G/A
Jun 10, 2022	kamin peter	11.1%	624,737	SC 13D/A
May 10, 2022	kamin peter	11.2%	624,737	SC 13D/A
Apr 21, 2022	kamin peter	11.2%	624,737	SC 13D/A
Feb 14, 2022	kubacki raymond c jr	6.0%	343,812	SC 13G/A
Feb 14, 2022	crawford investment counsel inc	4.81%	266,502	SC 13G/A

Recent SEC filings of Psychemedics Corp

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	SC 13G/A	Major Ownership Report
Jan 26, 2024	8-K	Current Report
Jan 24, 2024	4	Insider Trading

Peers (Alternatives to Psychemedics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	177.8B	23.9B	-3.62%	-6.01%	37.49	7.44	-10.33%	-33.23%
IDXX	40.7B	3.7B	-7.56%	1.70%	48.15	11.11	8.72%	24.44%
A	40.1B	6.7B	-7.27%	-2.45%	32.43	5.95	-2.81%	-6.58%
DGX	14.1B	9.3B	-0.67%	-10.95%	16.52	1.52	-6.38%	-9.73%
CRL	11.9B	4.1B	-10.25%	11.45%	25.15	2.89	3.86%	-2.39%
MEDP	11.8B	1.9B	-3.04%	96.75%	41.84	6.27	29.17%	15.26%
EXAS	11.6B	2.5B	10.66%	-3.39%	-56.78	4.64	19.93%	67.26%
NTRA	10.9B	1.1B	0.86%	77.04%	-25.08	10.07	31.99%	20.63%
MID-CAP
NEOG	2.6B	929.2M	-19.76%	-25.64%	1.7K	2.84	28.93%	111.61%
GH	2.0B	563.9M	-9.02%	-35.44%	-4.1	3.48	25.45%	26.76%
SMALL-CAP
CDNA	406.5M	280.3M	-22.58%	-16.13%	-2.14	1.45	-12.89%	-148.37%
ACRS	86.5M	31.2M	4.27%	-87.25%	-0.98	2.77	5.03%	-1.81%
AWH	42.6M	9.2M	-4.17%	-41.03%	-2.55	4.65	11.85%	44.12%
APDN	5.8M	9.0M	-8.11%	-66.99%	-0.8	0.64	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Psychemedics Corp News

Latest updates

Psychemedics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-12.4%	4,998	5,704	5,537	5,859	5,703	6,516	6,513	6,508	6,436	6,673	6,087	5,713	5,335	5,174	3,314	7,537	8,715	9,852	9,289	9,822	9,936
Gross Profit	-1.6%	2,058	2,091	2,059	2,205	2,246	2,332	2,273	2,441	2,185	3,075	2,436	2,568	1,277	1,133	-252	2,728	3,485	4,382	4,169	4,408	4,733
Operating Expenses	-8.5%	2,927	3,198	2,476	2,733	2,602	2,707	2,615	2,451	3,150	2,225	2,229	2,451	2,386	2,542	3,054	2,970	4,091	3,048	2,843	3,464	3,205
S&GA Expenses	2.4%	740	723	746	789	782	791	813	806	849	652	656	642	719	896	856	1,106	1,203	1,238	1,088	1,129	1,220
R&D Expenses	3.6%	285	275	286	298	323	328	357	318	313	244	293	280	299	305	345	331	354	393	400	420	462
EBITDA Margin	-21.2%	-0.15*	-0.13*	0.02*	0.04*	0.07*	0.00*	0.05*	0.07*	0.08*	0.12*	0.02*	-0.16*	-0.16*	-	-	-	-	-	-	-	-
Interest Expenses	0%	4.00	4.00	5.00	5.00	-3.00	17.00	9.00	10.00	10.00	12.00	14.00	14.00	15.00	17.00	20.00	23.00	12.00	9.00	21.00	17.00	25.00
Income Taxes	-93.0%	69.00	992	-196	-149	326	-286	-13.00	17.00	-435	186	73.00	20.00	-577	-319	-1,295	-156	-72.00	663	580	343	643
Earnings Before Taxes	20.9%	-876	-1,107	-922	-533	-362	-383	-351	56.00	-2,056	925	207	103	-1,120	-1,426	-3,345	-315	-602	1,340	1,348	970	1,524
EBT Margin	-21.3%	-0.16*	-0.13*	-0.09*	-0.07*	-0.04*	-0.11*	-0.05*	-0.03*	-0.03*	0.00*	-0.10*	-0.30*	-0.29*	-	-	-	-	-	-	-	-
Net Income	55.0%	-945	-2,099	-726	-384	-688	-97.00	-338	39.00	-1,621	739	134	83.00	-543	-1,107	-2,050	-159	-530	677	768	627	881
Net Income Margin	-10.0%	-0.19*	-0.17*	-0.08*	-0.06*	-0.04*	-0.08*	-0.05*	-0.03*	-0.03*	0.02*	-0.06*	-0.19*	-0.18*	-	-	-	-	-	-	-	-
Free Cashflow	155.0%	529	-962	-959	-245	1,767	2,283	318	335	451	-442	643	-420	1,029	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.6%	12,326	14,104	16,386	17,907	18,732	20,478	20,450	20,968	21,552	23,633	24,587	24,380	24,003	23,980	25,776	25,210	27,531	26,784	25,135	25,529	24,974
Current Assets	-13.6%	6,805	7,872	8,228	9,535	9,964	10,724	10,902	10,525	10,285	11,672	11,736	10,627	9,598	8,831	9,754	10,778	12,851	13,487	13,323	13,473	13,870
Cash Equivalents	43.4%	1,964	1,370	2,445	4,380	4,750	3,458	1,790	2,127	1,992	1,968	2,700	2,190	2,833	1,809	3,672	5,331	7,283	6,492	7,097	3,226	4,069
Net PPE	-	3,061	-	-	-	4,573	-	-	-	6,691	7,296	7,993	8,616	9,231	9,746	10,374	10,885	10,862	9,139	9,503	9,556	10,177
Liabilities	-15.3%	5,654	6,675	7,259	7,741	7,961	8,756	8,514	8,507	9,309	9,606	11,472	11,568	11,491	11,038	11,852	9,402	10,711	8,764	6,658	7,036	6,227
Current Liabilities	-12.6%	4,709	5,385	5,639	5,790	5,718	6,176	5,297	5,324	5,830	5,342	4,648	4,330	3,941	3,342	3,283	4,913	5,835	4,686	4,201	4,371	4,060
Long Term Debt	-100.0%	-	77.00	154	230	305	380	453	526	599	740	3,096	3,270	3,444	3,617	3,789	1,780	1,951	900	1,005	1,109	1,212
LT Debt, Current	1.0%	305	302	299	297	294	360	461	563	664	696	693	691	688	685	683	680	678	416	416	416	416
LT Debt, Non Current	-100.0%	-	77.00	154	230	305	380	453	526	599	740	3,096	3,270	3,444	3,617	3,789	1,780	1,951	900	1,005	1,109	1,212
Shareholder's Equity	-10.2%	6,672	7,429	9,127	10,166	10,771	11,722	11,936	12,461	12,243	14,027	13,115	12,812	12,512	12,942	13,924	15,808	16,820	18,020	18,477	18,493	18,747
Retained Earnings	-6.0%	-16,773	-15,828	-13,729	-12,602	-11,820	-10,733	-10,242	-9,511	-9,550	-7,650	-8,389	-8,523	-8,606	-8,063	-6,956	-4,906	-3,754	-2,232	-1,916	-1,690	-1,326
Additional Paid-In Capital	0.5%	35,129	34,941	34,540	34,452	34,275	34,139	33,863	33,657	33,478	33,362	33,189	33,020	32,803	32,690	32,564	32,412	32,249	31,999	31,809	31,681	31,523
Accumulated Depreciation	1.4%	23,633	23,312	22,877	22,428	21,964	21.00	20,867	20,272	19,659	19,024	18,529	17,609	16,937	16,257	15,565	14,903	16,197	15,530	14,820	14,094	13,341
Shares Outstanding	0.1%	5,806	5,802	5,743	5,686	5,681	5,645	5,626	5,590	5,589	5,542	5,541	5,537	5,524	-	-	-	-	-	-	-	-
Float	-	-	-	22,100	-	-	-	26,900	-	-	-	29,000	-	-	-	22,000	-	-	-	37,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	169.1%	662	-958	-959	-225	1,894	2,334	317	345	565	-388	650	-413	1,140	-1,494	-3,316	-413	948	1,671	1,322	368	3,922
Share Based Compensation	-53.4%	187	401	143	177	178	277	238	179	179	178	169	217	114	126	160	163	250	190	161	158	158
Cashflow From Investing	111.6%	5.00	-43.00	-48.00	-73.00	-20.00	-98.00	-54.00	-36.00	-26.00	-118	-17.00	-59.00	56.00	-237	-344	-333	-565	-826	3,580	-112	-4,220
Cashflow From Financing	1.4%	-73.00	-74.00	-928	-72.00	-582	-568	-600	-174	-515	-177	-172	-171	-172	-169	2,004	-1,162	321	-1,098	-1,130	-1,095	-2,023
Dividend Payments	-	-	-	-	-	399	394	-	-	279	-	-	-	-	-	-	993	992	993	994	991	991

PMD Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 22,098	$ 25,240
Cost of revenues	13,685	15,949
Gross profit	8,413	9,291
Operating Expenses:
General & administrative	7,192	5,857
Marketing & selling	2,998	3,191
Research & development	1,144	1,326
Total Operating Expenses	11,334	10,374
Operating (loss) income	(2,921)	(1,083)
Other Income (Expense):
Settlements	507	(0)
Other income (expense)	(10)	43
Total Other Income (Expense)	(517)	43
Net loss before provision for (benefit from) income taxes	(3,438)	(1,040)
Provision for (benefit from) income taxes	716	44
Net loss and comprehensive loss	$ (4,154)	$ (1,084)
Basic and diluted net loss per share (in dollars per share)	$ (0.72)	$ (0.19)
Weighted average common shares outstanding
Basic (in shares)	5,740	5,626
Diluted (in shares)	5,740	5,626

PMD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,964	$ 4,750
Accounts receivable, net of allowance for credit losses of $64 and $87 at December 31, 2023 and 2022, respectively	3,687	3,739
Prepaid expenses and other current assets	1,136	1,136
Income tax receivable	18	339
Total Current Assets	6,805	9,964
Property and equipment:
Computer software	4,774	4,648
Office furniture and equipment	2,253	2,247
Laboratory equipment	16,038	16,013
Leasehold improvements	3,629	3,629
Property, Plant and Equipment, Gross	26,694	26,537
Accumulated depreciation and amortization	(23,633)	(21,964)
Property, Plant and Equipment, Net	3,061	4,573
Other assets	632	823
Deferred tax assets	0	691
Operating lease right-of-use assets	1,828	2,681
Total Assets	12,326	18,732
Current Liabilities:
Accounts payable	752	448
Accrued expenses	2,604	3,939
Current portion of long-term debt	305	294
Current portion of operating lease liabilities	1,048	1,037
Total Current Liabilities	4,709	5,718
Long-term debt	0	305
Long-term portion of operating lease liabilities	945	1,938
Total Liabilities	5,654	7,961
Commitments and Contingencies
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.005 par value; 50,000 shares authorized 6,474 shares and 6,349 shares issued at December 31, 2023 and 2022, respectively, 5,806 shares outstanding and 5,681 shares outstanding at December 31, 2023 and 2022, respectively	32	32
Additional paid-in capital	35,129	34,275
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated deficit	(16,773)	(11,820)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	6,672	10,771
Total Liabilities and Shareholders' Equity	$ 12,326	$ 18,732

About Psychemedics Corp

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

CEO	Mr. Brian Hullinger
WEBSITE	psychemedics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	133

Psychemedics Corp Frequently Asked Questions

What is the ticker symbol for Psychemedics Corp? What does PMD stand for in stocks?

PMD is the stock ticker symbol of Psychemedics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Psychemedics Corp (PMD)?

As of Tue Apr 16 2024, market cap of Psychemedics Corp is 14.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMD stock?

You can check PMD's fair value in chart for subscribers.

What is the fair value of PMD stock?

You can check PMD's fair value in chart for subscribers. The fair value of Psychemedics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Psychemedics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Psychemedics Corp a good stock to buy?

The fair value guage provides a quick view whether PMD is over valued or under valued. Whether Psychemedics Corp is cheap or expensive depends on the assumptions which impact Psychemedics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMD.

What is Psychemedics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, PMD's PE ratio (Price to Earnings) is -3.58 and Price to Sales (PS) ratio is 0.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Psychemedics Corp's stock?

In the past 10 years, Psychemedics Corp has provided -0.149 (multiply by 100 for percentage) rate of return.